Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristian Reich

Showing results (61-70 of 265) with videos related to

Pageof 27
Sort By:
Archives of Dermatological Research|April 17, 2013
National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelinesAlexander Nast, Ulrich Mrowietz, Knud Kragballe, et al.
Dermatology (Basel, Switzerland)|May 14, 2015
Epidemiology and Comorbidity in Children with Psoriasis and Atopic EczemaMatthias Augustin, Marc A Radtke, Gerd Glaeske, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 20, 2008
Quality of psoriasis care in Germany--results of the national study PsoHealth 2007Matthias Augustin, Kristian Reich, Christine Reich, et al.
Journal of Drugs in Dermatology : JDD|February 8, 2022
Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or UstekinumabMathias Augustin, Gaia Gallo, Kyoungah See, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 12, 2006
[Therapy of psoriasis-arthritis and psoriasis vulgaris with infliximab]Ulrich Mrowietz, Joachim Barth, Wolf-Henning Boehncke, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 1, 2006
[Therapy of psoriasis vulgaris with efalizumab]Ulrich Mrowietz, Joachim Barth, Wolf-Henning Boehncke, et al.
Archives of Dermatological Research|November 4, 2008
Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgarisRotraut Mössner, Gerthild Stiens, Inke R König, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial ResultsRichard G B Langley, Kristian Reich, Charis Papavassilis, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 22, 2005
[The role of biologics into the management of psoriasis: a consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung]Boehncke Wolf-Henning, Markus Friedrich, Ulrich Mrowietz, et al.
The Journal of Dermatological Treatment|July 16, 2019
Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumabKristian Reich, Peter Foley, Chenglong Han, et al.
Pageof 27

Showing results (61-70 of 265) with videos related to

Sort By:
Pageof 27
Archives of Dermatological Research|April 17, 2013
National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelinesAlexander Nast, Ulrich Mrowietz, Knud Kragballe, et al.
Dermatology (Basel, Switzerland)|May 14, 2015
Epidemiology and Comorbidity in Children with Psoriasis and Atopic EczemaMatthias Augustin, Marc A Radtke, Gerd Glaeske, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 20, 2008
Quality of psoriasis care in Germany--results of the national study PsoHealth 2007Matthias Augustin, Kristian Reich, Christine Reich, et al.
Journal of Drugs in Dermatology : JDD|February 8, 2022
Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or UstekinumabMathias Augustin, Gaia Gallo, Kyoungah See, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 12, 2006
[Therapy of psoriasis-arthritis and psoriasis vulgaris with infliximab]Ulrich Mrowietz, Joachim Barth, Wolf-Henning Boehncke, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 1, 2006
[Therapy of psoriasis vulgaris with efalizumab]Ulrich Mrowietz, Joachim Barth, Wolf-Henning Boehncke, et al.
Archives of Dermatological Research|November 4, 2008
Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgarisRotraut Mössner, Gerthild Stiens, Inke R König, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial ResultsRichard G B Langley, Kristian Reich, Charis Papavassilis, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 22, 2005
[The role of biologics into the management of psoriasis: a consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung]Boehncke Wolf-Henning, Markus Friedrich, Ulrich Mrowietz, et al.
The Journal of Dermatological Treatment|July 16, 2019
Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumabKristian Reich, Peter Foley, Chenglong Han, et al.
Pageof 27